Development of a regimen for rapid initiation of perhexiline therapy in acute coronary syndromes

Internal Medicine Journal

Volumn 34, Issue 6, 2004, Pages 361-363

  Philpott, A ^a   Chandy, S ^a,b   Morris, R ^a   Horowitz, J D ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Angina pectoris; Overdose; Perhexiline; Pharmacokinetics

Indexed keywords

PERHEXILINE;

ACUTE HEART FAILURE; ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING;

ADULT; CARDIOVASCULAR AGENTS; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; OVERDOSE; PERHEXILINE; SELF MEDICATION;

EID: 3242751956     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00624.x     Document Type: Article

References (17)

1. Brown MJ, Horowitz JD, Mashford ML. A double-blind trial of perhexiline maleate in the prophylaxis of angina pectoris. Med J Aust 1976; 1: 260-63.
2. Cole PL, Beamer AD, McGowan N, Cantillon CO, Benfell K, Kelly R. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-70.
3. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ. Perhexiline maleate treatment for sever angina pectoris - correlations with pharmacokinetics. Int J Cardiol 1986; 13: 219-29.
4. Stewart S, Voss DW, Northey DL, Horowitz JD. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit 1996; 18: 635-9.
5. Willoughby SR, Chirkov YY, Kennedy JA, Horowitz JD. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 2002; 23: 1946-54.
6. Fournier C, Bourmayan C, Barrillon A, Gerbaux A. Complications following perhexiline maleate treatment. Coeur Med Interne 1978; 17: 553-9.
7. Dally S, Lagier G, Assan R, Gaultier M. Hypoglycaemia in two patients treated with perhexiline maleate. Nouvelle Presse Medicale 1977; 6: 1643-4.
8. Walker BD, Valenzuela SM, Singleton CB, Tie H, Bursill JA, Wyse KR. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate. Br J Pharmacol 1999; 127: 243-51.
9. Kerr GD, Ingham G. Torsade de Pointes associated with perhexiline maleate therapy. Aust N Z J Med 1990; 20: 818-20.
10. Horowitz JD, Morris PM, Drummer OH, Goble AJ, Louis WJ. High-performance liquid chromatographic assay of perhexiline maleate in plasma. J Pharm Sci 1981; 70: 320-22.
11. Hussein R, Charles BG, Morris PM, Rasiah RL. Population pharmacokinetics of perhexiline from very sparse, routine monitoring data. Ther Drug Monit 2001; 23: 636-43.
12. Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996; 52: 273-80.
13. Malmberg K, Norhammer A, Ryden L. Insulin treatment post myocardial infarction: the DIGAMI study. Adv Exp Med Biol 2001; 498: 279-84.
14. Aroney C, Boyden AN, Jelinek MV, Thompson P, Tonkin AM, White H. Current guidelines for the management of unstable angina: a new diagnostic and management paradigm. Intern Med J 2001; 31: 104-11.
15. Guengerich FP. Role of cytochrome P450 enzymes in drug-drug interactions [Review]. Adv Pharmacol 1997; 43: 7-35.
16. Nyfort-Hansen K. Perhexiline toxicity related to citalopram use. Med J Aust 2002; 31: 104-11.
17. Ritchie RH, Morgan DJ, Horowitz JD. Myocardial effect compartment modelling of metoprolol and sotalol: importance of myocardial subsite drug concentration. J Pharm Sci 1998; 87: 177-82.